Avalon and GSK launch and fund three new life science companies

Avalon Ventures and GlaxoSmithKline has launched Adrenergics Inc, CadheRx Therapeutics Inc and Calporta Therapeutics Inc, three San Diego-based early-stage life science companies. Each will receive up to $10 million in Series A funding as well as R & D support from Avalon Ventures and GSK.


GSK buys GlycoVaxyn for $212 mln

Sofinnova Partners has sold GlycoVaxyn to GlaxoSmithKline for $212 million. Schlieren, Switzerland-based GlycoVaxyn develops conjugate vaccines to treat bacterial infections. GSK was a minority investor of GlycoVaxyn.

Atopix picks up funding from SR One

Atopix has received an undisclosed investment from SR One, the corporate venture capital arm of GlaxoSmithKline. Also, the company has added Dr. Deborah Harland, a partner at SR One, to its board of directors. Based in the UK, Atopix is a biopharmaceutical company focused on treating allergic disease.


Avalon Ventures and GSK launch and fund Silarus and Thyritope

Avalon Ventures and GlaxoSmithKline has launched Silarus Therapeutics and Thyritope Biosciences, two San Diego-based early-stage life science firms. Both will receive up to $10 million in Series A funding as well as R & D support from Avalon Ventures and GSK.

RuiYi nets $15 mln Series B funds

Sino-American biotech company RuiYi said Thursday that it has raised $15 million in Series B financing. The investors were 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.

GSK logo shot by Luke MacGregor of Reuters

Reuters: GlaxoSmithKline Launches $50M VC Fund

GlaxoSmithKline on Thursday announced a $50 million venture fund and said the fund’s first investment was made in SetPoint Medical, which is working on implantable devices to treat inflammatory diseases, Reuters reported.

Epizyme Files for an IPO

Epizyme, a six-year-old, Cambridge, Mass.-based biopharmaceutical company that’s focused on researching treatments for tumors and blood cancer, has filed an S-1 with the SEC.

OncoMed Promotes

OncoMed Pharmaceuticals, a clinical-stage company developing therapeutics that target cancer stem cells, has promoted Jakob Dupont, formerly vice president, clinical research to senior vice president and chief medical officer. Privately-held, OncoMed’s investors include US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay […]

Amplimmune Signs Big Deal with GSK

Amplimmune has signed a drug development deal with GlaxoSmithKline that includes a $23 million up-front payment and up to $485 million in milestone payments. The agreement relates to PD-1 targeting therapies that may help treat cancer and other diseases. Rockville, Md.-based Amplimmune has raised $20 million from InterWest Partners and Wellcome Trust.

Aptuit Buys GSK’s Medicines Research Center in Italy

Aptuit has bought GlaxoSmithKline’s Medicines Research Center in Verona, Italy. The arrangement is effective July 1. Financial terms were not disclosed. Aptuit, a pharmaceutical services company, is a portfolio company of Welsh, Carson, Anderson & Stowe. GSK is a research-based pharmaceutical and healthcare company.

GSK Completes Stiefel Labs Purchase

GlaxoSmithKline has completed its acquisition on Stiefel Laboratories Inc., a Coral Gables, Fla.-based skincare pharmaceutical company that had been partially owned by The Blackstone Group. The $3.6 billion acquisition included $2.9 billion in cash, up to $300 million in cash earn-out payments and the assumption of $400 million in net debt. Blackstone had acquired an 18% stake for $484 million in August 2007.

VC-Backed Chroma Signs $1 Billion Deal with Glaxo

LONDON (Reuters) – GlaxoSmithKline (GSK.L) has signed a deal with Chroma Therapeutics, giving it access to the unlisted British biotech company’s experimental compounds for inflammatory diseases such as rheumatoid arthritis. The move boosts Glaxo’s early-stage pipeline but will not deliver products to the market for many years as Chroma’s inflammation programmes have yet to enter […]

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget